UNITED STATES: LATEST INTERVIEWS MORE INTERVIEWS

"Based on our in vivo data for our lead CEACAM1/5 antibody YB-200, we have obtained orphan drug status from FDA for the treatment of liver cancer."
"The US leads innovation, so if you are not heavily invested there in pharma, you are in trouble. Lots of our clients are shifting their production from Asia, so the US will remain critical to Evonik Health Care’s growth."
"We want to pioneer a commodity utility approach for needed areas of pharmaceutical manufacturing, and make that available as a sustainable platform that any country can start with and innovate from."
"Experienced CDMOs can provide companies with access to new formulation and technology methods that improve the bioavailability of difficult-to-formulate compounds."

UNITED STATES: LATEST ARTICLES

Mine Water Stewardship in Arizona

June 01, 2023
Expert Opinion Article by Terry Braun, President, North America, SRK Consulting

Protecting Supply Chains and Prosperity: The Case for Reducing US Dependency on Foreign Critical Minerals

October 12, 2022
Expert Opinion Article by Eric Mears, Vice President, Haley & Aldrich

Arizona Copper Production: Securing a Domestic Supply Chain

October 10, 2022
Arizona, leading the charge towards the green transition

UNITED STATES: RECENTLY RELEASED PUBLICATIONS

MACIG

SPANISH

SUBSCRIBE TO OUR NEWSLETTER

RECENTLY PUBLISHED

United States Life Sciences 2023

In many ways, 2022 was a turning point for the US life sciences industry. After having provided a lightning-quick response to the Covid-19 pandemic, the industry gathered the lessons learned and sought a sense of normalcy to continue developing necessary drugs for patients worldwide. Yet, the geopolitical, macroeconomic, and regulatory environments all come with their set of challenges, forcing executives into increasingly complex decisions when defining their strategies.

PARTNER EVENTS